Proceedings of the 12th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2024
Vol. 3 No. s1 (2024)
Patient and public involvement in cancer-associated thrombosis research: necessary or glorified tokenism?
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 6 February 2024
Accepted: 11 March 2024
Accepted: 11 March 2024
1222
Views
295
Downloads
Authors
The advantages of patient and public involvement (PPI) in research are becoming more widely known, however different research organizations have different rates of adoption. Comparably, some groups provide tokenistic participation in the research process, which is inconsistent with the extent to which PPI partners are truly involved. Recent developments in the field of cancer-associated thrombosis (CAT) research have shown how crucial PPI is to the foundation of the entire research process, from formulating the research question to disseminating the findings. This manuscript aims to present an overview of PPI within the framework of CAT research and demonstrate how, when used appropriately, PPI can improve a project’s overall success, rigor, and relevance.
Downloads
Download data is not yet available.
Citations
Jones M, Chilton J, Feather L. Salute to Satchmo. London: I.P.C. Specialist & Professional Press Ltd. 1970:155.
Andrews LM, Allen H, Sheppard ZA, et al. More than just ticking a box… how patient and public involvement improved the research design and funding application for a project to evaluate a cycling intervention for hip osteoarthritis. Res Involv Engagem 2015;1:13. DOI: https://doi.org/10.1186/s40900-015-0013-8
Supple D, Roberts A, Hudson V, et al. From tokenism to meaningful engagement: best practices in patient involvement in an EU project. Res Involv Engagem 2015;1:5. DOI: https://doi.org/10.1186/s40900-015-0004-9
Health Research Authority (HRA). Public Involvement. 2022. Available from: https://www.hra.nhs.uk/planning-andimproving-research/best-practice/public-involvement
Engagement NC-oCfP. Introducing Public Engagement. 2023. Available from: https://www.publicengagement.ac.uk/about-engagement/what-public-engagement
Feynman C, Feynman M. The Pleasure of Finding Things Out. 1st ed. United States: Perseus Books 1999:270.
Partnership UPISD. UK Standards for Public Involvement: Better public involvement for better health and social care research. NIHR 2019. Available from: https://sites.google.com/nihr.ac.uk/pi-standards/home
White C, Noble S, Swan F, et al. ‘Hospice inpatient deep vein thrombosis detection (HIDDen) in advanced non malignant diseases’: a longitudinal pilot study. BMJ Support Palliat Care 2022;12:e767-e70. DOI: https://doi.org/10.1136/bmjspcare-2019-002039
Seddon K, Elliott J, Johnson M, et al. Using the United Kingdom standards for public involvement to evaluate the impact of public involvement in a multinational clinical study. Res Involv Engagem 2021;7:22. DOI: https://doi.org/10.1186/s40900-021-00264-3
Centre. MCRCatWCR. Public Involvement in Research Impact Toolkit (PIRIT) https://www.cardiff.ac.uk/marie-curieresearch-centre/patient-and-public-involvement/public-involvement-in-research-impact-toolkit-pirit2023
Kitson T, Osborne E, Noble S, et al. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 2023;13:e073049. DOI: https://doi.org/10.1136/bmjopen-2023-073049
Goedegebuur J, Abbel D, Accassat S, et al. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool. Thromb Res 2023;228:54-60. DOI: https://doi.org/10.1016/j.thromres.2023.05.008
How to Cite
1.
Noble S. Patient and public involvement in cancer-associated thrombosis research: necessary or glorified tokenism?. Bleeding Thromb Vascul Biol [Internet]. 2024 May 16 [cited 2025 Sep. 5];3(s1). Available from: https://www.btvb.org/btvb/article/view/125
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Betül Ünlü, Neha Joshi, Jamie M. O'Sullivan, Endothelial cell dysfunction in cancer: a not-so-innocent bystander , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Benedetta Izzi, Simona Costanzo, Alessandro Gialluisi, Amalia De Curtis, Sara Magnacca, Teresa Panzera, Augusto Di Castelnuovo, Maria Benedetta Donati, Chiara Cerletti, Marc F. Hoylaerts, Giovanni de Gaetano, Licia Iacoviello, *on behalf of the Moli-sani Study Investigators, Platelet distribution width is associated with cardiovascular mortality in an adult general population , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Setor K. Kunutsor, Sudhir Kurl, Ari Voutilainen, Jari Laukkanen, Circulating albumin-to-fibrinogen ratio may be a risk indicator for venous thromboembolism: findings from a population-based prospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Maria Barca-Hernando, Victor Garcia-Garcia, Luis Jara-Palomares, Location of metastasis and complications in patients with venous thromboembolism and cancer: a systematic review , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Kristen M. Sanfilippo, Tzu-Fei Wang, Venous thromboembolism and mortality in patients with hematological malignancies , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Vittorio Pengo, Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial" , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 2 (2025)
- Sarah Gallitto, Thomas C. Varkey, Jacob Lahti, Venous thromboembolism prophylaxis in orthopedic surgery: a narrative review , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Daniela Poli, Riccardo Tartaglia, Doris Barcellona , Paolo Bucciarelli , Antonio Ciampa, Elvira Grandone, Giuseppe Malcangi, Giuseppe Rescigno, Vincenzo Toschi, Sophie Testa, Alessandro Squizzato, Attitude to clinical research among health professionals affiliated with the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Ronda Lun, Deborah M. Siegal, Cancer-associated ischemic stroke: current knowledge and future directions , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
You may also start an advanced similarity search for this article.
